Cite
HARVARD Citation
Andrade Campos, M. et al. (n.d.). Short course of R‐HyperCVAD/MTX/ARA‐C followed by ASCT as first‐line therapy in mantle cell lymphoma patients prolongs progression‐free survival to more than 9 years. Hematological oncology. pp. 359-360. [Online].